Molecular Markers for Colorectal Cancer.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Surgical Clinics of North America

• Publication date

  2017-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.suc.2017.01.014PMID 28501255
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Immunotherapy in colorectal cancer: What have we learned so far?

  2016influential reference
• Lessons Learned From the Quest for Gene Signatures That Predict Treatment Response in Rectal Cancer.

  2016cited by this paper
• Challenging a dogma: co-mutations exist in MAPK pathway genes in colorectal cancer

  2016cited by this paper
• Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma

  2016influential reference
• TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: A potential novel approach to the treatment of metastatic colorectal cancer

  2016cited by this paper
• Should We Give Up The Search for a Clinically Useful Gene Signature for the Prediction of Response of Rectal Cancer to Neoadjuvant Chemoradiation?

  2016cited by this paper
• Molecular Evaluation of Colorectal Adenocarcinoma: Current Practice and Emerging Concepts.

  2016influential reference
• Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial.

  2015cited by this paper
• The prevalent KRAS exon 2 c.35 G>A mutation in metastatic colorectal cancer patients: A biomarker of worse prognosis and potential benefit of bevacizumab-containing intensive regimens?

  2015cited by this paper
• Comprehensive evaluation of the effectiveness of gene expression signatures to predict complete response to neoadjuvant chemoradiotherapy and guide surgical intervention in rectal cancer.

  2015cited by this paper
• Genetics and Genetic Biomarkers in Sporadic Colorectal Cancer.

  2015influential reference
• Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.

  2015cited by this paper
• PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

  2015cited by this paper
• PD-1 blockade in tumors with mismatch repair deficiency.

  2015cited by this paper
• A Comprehensive Review of Clinical Trials on EGFR Inhibitors Such as Cetuximab and Panitumumab as Monotherapy and in Combination for Treatment of Metastatic Colorectal Cancer

  2015influential reference
• Bevacizumab: A Review of Its Use in Advanced Cancer

  2014cited by this paper
• Differential expression of p53 family proteins in colorectal adenomas and carcinomas: Prognostic and predictive values.

  2014cited by this paper
• Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial.

  2013cited by this paper
• Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin.

  2013cited by this paper
• Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581.

  2013cited by this paper
• The blockade of immune checkpoints in cancer immunotherapy

  2012influential reference
• IL-18 induces PD-1-dependent immunosuppression in cancer.

  2011cited by this paper
• New monoclonal antibodies against B-cell antigens: possible new strategies for diagnosis of primary cutaneous B-cell lymphomas.

  2011cited by this paper
• HLA-A*0201-restricted CEA-derived Peptide CAP1 Is Not a Suitable Target for T-cell-based Immunotherapy

  2010cited by this paper
• Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer.

  2010cited by this paper
• Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer.

  2010cited by this paper
• The diagnostic value of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) determination in the sera of colorectal adenoma and cancer patients

  2010influential reference
• Prognostic impact of extracellular matrix metalloprotease inducer

  2009influential reference
• Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.

  2009cited by this paper
• Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.

  2009cited by this paper
• Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired.

  2009cited by this paper
• Human prostate‐infiltrating CD8+ T lymphocytes are oligoclonal and PD‐1+

  2009cited by this paper
• The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer.

  2009cited by this paper
• Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.

  2009influential reference
• Irinotecan therapy and molecular targets in colorectal cancer: a systemic review.

  2009cited by this paper
• PD-1 and its ligands in tolerance and immunity.

  2008cited by this paper
• Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4

  2008cited by this paper
• Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigenetics.

  2008influential reference
• Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

  2008cited by this paper
• PD-1 and PD-1 ligands: from discovery to clinical application.

  2007cited by this paper
• Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.

  2006influential reference
• Restoring function in exhausted CD8 T cells during chronic viral infection

  2006cited by this paper
• Reversal of the TCR Stop Signal by CTLA-4

  2006cited by this paper
• Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.

  2006cited by this paper
• Tissue expression of PD-L1 mediates peripheral T cell tolerance

  2006cited by this paper
• Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.

  2005cited by this paper
• The MAPK signalling pathways and colorectal cancer.

  2005influential reference
• Induction of antigen‐specific CD4‐ and CD8‐mediated T‐cell responses by fusions of autologous dendritic cells and metastatic colorectal cancer cells

  2005cited by this paper
• Dendritic Cells Fused with Allogeneic Colorectal Cancer Cell Line Present Multiple Colorectal Cancer–Specific Antigens and Induce Antitumor Immunity against Autologous Tumor Cells

  2005cited by this paper
• B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression

  2004cited by this paper
• Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

  2004cited by this paper
• CpG island methylator phenotype in cancer

  2004influential reference
• Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine.

  2004cited by this paper
• Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial.

  2004cited by this paper
• CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms

  2004cited by this paper
• Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines.

  2003cited by this paper
• Mitogen activated protein (MAP) kinase signal transduction pathways and novel anti-inflammatory targets

  2003cited by this paper
• Role of APC and DNA mismatch repair genes in the development of colorectal cancers

  2003influential reference
• Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

  2003cited by this paper
• Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

  2002cited by this paper
• Cutting Edge: CTLA-4 (CD152) Differentially Regulates Mitogen-Activated Protein Kinases (Extracellular Signal-Regulated Kinase and c-Jun N-Terminal Kinase) in CD4+ T Cells from Receptor/Ligand-Deficient Mice1

  2002cited by this paper
• Impact of the oxaliplatin-5 fluorouracil-folinic acid combination on respective intracellular determinants of drug activity

  2002cited by this paper
• Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

  2002cited by this paper
• Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptors

  2002cited by this paper
• COX‐2 inhibitors and colorectal cancer chemoprevention

  2002cited by this paper
• Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice.

  2001cited by this paper
• Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.

  2001influential reference
• Sporadic colorectal cancers with microsatellite instability and their possible origin in hyperplastic polyps and serrated adenomas.

  2001cited by this paper
• Host cyclooxygenase-2 modulates carcinoma growth.

  2000cited by this paper
• Cyclic GMP mediates apoptosis induced by sulindac derivatives via activation of c-Jun NH2-terminal kinase 1.

  2000cited by this paper
• Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase.

  2000cited by this paper
• Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation

  2000cited by this paper
• Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.

  2000cited by this paper
• Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer.

  2000cited by this paper
• The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.

  2000cited by this paper
• Overexpression of keratinocyte growth factor in cancer cells and enterochromaffin cells in human colorectal cancer

  2000cited by this paper
• Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.

  2000cited by this paper
• Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.

  2000cited by this paper
• Colorectal liver metastasis thymidylate synthase staining correlates with response to hepatic arterial floxuridine.

  1999cited by this paper
• CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR.

  1999cited by this paper
• Concurrent irinotecan and 5-fluorouracil plus levo-folinic acid given every other week in the first-line management of advanced colorectal carcinoma: a phase I study of the Southern Italy Cooperative Oncology Group.

  1999cited by this paper
• Cell‐type‐specific activation of c‐Jun N‐terminal kinase by salicylates

  1999cited by this paper
• Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor.

  1999cited by this paper
• Fluoropyrimidines as Antifolate Drugs

  1999cited by this paper
• A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial.

  1998cited by this paper
• Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer.

  1998influential reference
• Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study.

  1998influential reference
• Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin.

  1997cited by this paper
• A comprehensive review of 5‐fluorouracil and leucovorin in patients with metastatic colorectal carcinoma

  1997cited by this paper
• High frequency of K-ras mutations in human colorectal hyperplastic polyps.

  1997cited by this paper
• [Oxaliplatin, folinic acid and 5-fluorouracil (folfox) in pretreated patients with metastatic advanced cancer. The GERCOD].

  1997cited by this paper
• Oxaliplatine, acide folinique et 5-fluorouracile (folfox) en seconde ligne thérapeutique du cancer colorectal métastasé

  1997cited by this paper
• Aspirin and the risk of colorectal cancer in women.

  1996cited by this paper
• Molecular nature of colon tumors in hereditary nonpolyposis colon cancer, familial polyposis, and sporadic colon cancer.

  1996cited by this paper
• Therapeutic efficacy of fluoropyrimidines depends on the duration of thymidylate synthase inhibition in the murine colon 26-B carcinoma tumor model.

  1996cited by this paper
• Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival.

  1996cited by this paper
• The effect of dose and interval between 5-fluorouracil and leucovorin on the formation of thymidylate synthase ternary complex in human cancer cells.

  1995cited by this paper
• Selected eicosanoids increase the proliferation rate of human colon carcinoma cell lines and mouse colonocytes in vivo.

  1995cited by this paper
• Aspirin and related nonsteroidal anti-inflammatory drugs as chemopreventive agents against colon cancer.

  1995cited by this paper
• Aspirin and the risk of colorectal cancer in women.

  1995cited by this paper

• Significance and Correlation Analysis of Folate Receptor‐Positive Circulating Tumor Cells (FR + CTC) in Colorectal Cancer Patients

  2026cites this paper
• Evaluation of Epigenetic Markers in the Diagnosis and Prognosis of Colorectal Cancer

  2025cites this paper
• Predictive and Prognostic Biomarkers of Recurrence in Locoregional Colorectal Cancer

  2025cites this paper
• RAF1 contributes to cell proliferation and STAT3 activation in colorectal cancer independently of microsatellite and KRAS status

  2023cites this paper
• Toward Early Diagnosis of Colorectal Cancer: Focus on Optical Nano Biosensors.

  2022cites this paper
• Targeted Therapy for Colorectal Cancer.

  2022cites this paper
• Inhibition of the Wnt/b-catenin pathway using PNU-74654 reduces tumor growth in in vitro and in vivo models of colorectal cancer.

  2022cites this paper
• ASSOCIATION BETWEEN RESILIENCE AND QUALITY OF LIFE IN PATIENTS WITH COLON CANCER

  2022cites this paper
• Multiple myeloma driving factor WHSC1 is a transcription target of oncogene HMGA2 that facilitates colon cancer proliferation and metastasis.

  2021cites this paper
• Study of mechanisms of cell death induction by the essential oil Aloysia citriodora and its major component, citral, and evaluation of their potential synergistic effects with oxaliplatin in human colon cancer cells

  2021cites this paper
• Emerging agents that target signaling pathways to eradicate colorectal cancer stem cells

  2021cites this paper
• Synthesis, Biological, and Molecular Docking Studies on 4,5,6,7-Tetrahydrobenzo[b]thiophene Derivatives and Their Nanoparticles Targeting Colorectal Cancer

  2021cites this paper
• Electrochemical biosensors for measurement of colorectal cancer biomarkers

  2021cites this paper
• Long non-coding RNA LINP1 promotes the malignant progression of prostate cancer by regulating p53.

  2021cites this paper
• Treating colon cancers with a non-conventional yet strategic approach: An overview of various nanoparticulate systems.

  2021cites this paper
• Multi-center real-world comparison of the fully automated Idylla™ microsatellite instability assay with routine molecular methods and immunohistochemistry on formalin-fixed paraffin-embedded tissue of colorectal cancer

  2020cites this paper
• Neoadjuvant chemoradiotherapy might provide survival benefit in patients with stage IIIb/IIIc locally advanced rectal cancer: A retrospective single‐institution study with propensity score‐matched comparative analysis

  2020cites this paper
• Increased Temperature Facilitates Adeno-Associated Virus Vector Transduction of Colorectal Cancer Cell Lines in a Manner Dependent on Heat Shock Protein Signature

  2020cites this paper
• Host microbiomes and disease

  2020cites this paper
• Colorectal Cancer Early Detection in Stool Samples Tracing CpG Islands Methylation Alterations Affecting Gene Expression

  2020cites this paper
• Downregulation of ORP3 Correlates with Reduced Survival of Colon Cancer Patients with Advanced Nodal Metastasis and of Female Patients with Grade 3 Colon Cancer

  2020cites this paper
• Biomarkers and intermediate-high risk non-muscle invasive bladder cancer: a multivariate analysis of three different cellular pathways with pronostic implications

  2020cites this paper
• Knockdown of Forkhead box A1 suppresses the tumorigenesis and progression of human colon cancer cells through regulating the phosphatase and tensin homolog/Akt pathway

  2020cites this paper
• The management of the colorectal cancer: Perspectives

  2020cites this paper
• Evaluation of Laparoscopic Colectomy for Colonic Cancer in Minia University Hospital (prospective study)

  2020cites this paper
• Surgical and survival outcomes of laparoscopic colectomy for trans-verse colon cancer in elderly patients.

  2019cites this paper
• Relationships between adherence to the Mediterranean diet and methylation of WNT pathway-related genes implicated in colorectal cancer

  2019influential citation
• Tumor-induced DNA methylation in the white blood cells of patients with colorectal cancer

  2019cites this paper
• Adiponectin and colon cancer: evidence for inhibitory effects on viability and migration of human colorectal cell lines

  2018cites this paper
• Primary Tumor Location in Colorectal Cancer: Comparison of Right- and Left-Sided Colorectal Cancer Characteristics for the Interventional Radiologist

  2018cites this paper
• COLORECTAL CANCER IMMUNOTHERAPY

  2018influential citation
• Short- and long-term outcomes of laparoscopic complete mesocolic excision for transverse colon cancer.

  2018cites this paper
• Dynamic Institutionalization of Research in the Field of Colorectal Tumour Markers

  2018cites this paper
• Reciprocal Regulation among miR-181d/CRY2/FBXL3/c-myc Signaling Axis Modulates Metabolism in Colorectal Cancer

  2017cites this paper
• Beta-catenin complexes in colorectal cancer

  2015cites this paper
• Long non-coding RNA DLEU 7-AS 1 promotes the occurrence and development of colorectal cancer via Wnt / β-catenin pathway

  year unknowncites this paper
• World Journal of Gastrointestinal Oncology

  year unknowncites this paper